Pembrolizumab plus axitinib combination accepted by NHS Scotland for first-line treatment of advanced kidney cancer

The Sottish Medicine Consortium (SMC) have issued a final decision to recommend the pembrolizumab plus axitinib combination as a first-line treatment for advanced kidney cancer. We are delighted that as from today, kidney cancer patients in Scotland can get NHS funding for pemrolizumab in combination with axitinib for untreated patients with advanced or metastatic renal cell […]

read more

Pembrolizumab plus axitinib combination declined for first-line treatment of advanced kidney cancer

The National Institute for Health and Care Excellence (NICE) have issued a final decision not to recommend the pembrolizumab plus axitinib combination as a first-line treatment for advanced kidney cancer, despite it’s proven effectiveness at prolonging the life of kidney cancer patients. In their Final Appraisal Document (FAD) released today, NICE stated that there was uncertainty about the long-term benefits of the pembrolizumab plus axitinib […]

read more

ASCO 2020: Pembrolizumab/axitinib combination for the treatment of advanced kidney cancer

Updated results from the KEYNOTE-426 study of pembrolizumab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma (RCC) were presented during the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program over the weekend. The combination of pembrolizumab with axitinib continues to show improved efficacy in the treatment of advanced RCC […]

read more

Promising activity of pembrolizumab plus bevacizumab for metastatic kidney cancer

Results from a phase Ib/II study published in Journal of Clinical Oncology last month show encouraging activity of a novel immunotherapy and VEGF inhibitor combination in metastatic renal cell carcinoma (mRCC). In the phase Ib part of the study, which was used to find the safest and most tolerated dose of the combination, there were […]

read more

NICE draft guidance refuses pembrolizumab plus axitinib combination

The National Institute for Health and Care Excellence (NICE) have issued an interim decision not to recommend the pembrolizumab plus axitinib combination as a first-line treatment for advanced kidney cancer, despite it’s proven effectiveness at prolonging the life of kidney cancer patients. In their Appraisal Consultation Document (ACD) released this week, NICE stated that there was uncertainty about the long-term […]

read more

Lenvatinib plus pembrolizumab shows promise in solid tumours

The combination of lenvatinib plus pembrolizumab has shown promise in a phase Ib/II clinical trial in 137 patients with various advanced solid tumours and no standard treatment options available. The objective response rate at 24 weeks (the primary objective) was highest in renal cell carcinoma (63%), endometrial cancer (52%), and melanoma (48%). The combination was […]

read more

New first-line immunotherapy plus TKI combinations for metastatic kidney cancer

Approval of axitinib plus pembrolizumab and axitinib plus avelumab in the first-line treatment of metastatic renal cell carcinoma (RCC) by both the Food and Drug Administration (FDA) in America and the European Commission represent milestone events for the treatment of metastatic RCC in 2019. Approval of the avelumab plus axitinib combination was based on the […]

read more

Pilot study of radiation therapy plus pembrolizumab for kidney cancer

A recent publication in the American Journal of Clinical Oncology this month reports on part of an exploratory study to look at the effect of radiotherapy alone or in combination with pembrolizumab on the immune system, and to determine the efficacy of this treatment in patients with solid tumours. This is the first study to […]

read more

Deciding on the ideal first-line treatment for rare and advanced kidney cancer

Currently, doctors are unsure which is the best first-line treatment for patients with rare and advanced kidney cancers. During a debate at the 18th International Kidney Cancer Symposium (IKCS), 5 doctors discussed their opinions. During the debate, the use of immunotherapy versus targeted kinase inhibitors (TKI) for the first-line treatment of advanced non-clear cell renal […]

read more

Comparison of first-line immunotherapy combinations for advanced kidney cancer

In this paper, three clinical trials with immunotherapy combinations for the first-line treatment of clear renal cell carcinoma (RCC) are discussed. Dr  Robert Motzer from Memorial Sloan Kettering Cancer Center in New York compared the findings from the three trials at the Annual Chemotherapy Foundation Symposium (CFS) in New York last week. All three phase […]

read more
Showing 1 to 10 of 45 results
  TOP